We are 4-Pyridazinecarboxylic acid CAS:50681-25-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
Items of Analysis | Standard of Analysis | Test Results |
Appearance | Off-white powder | Conforms |
Purity | ≥98.0% | 98.34% |
Water | ≤0.5% | 0.22% |
Conclusion | Conforms to Factory Standard |
Related News: The use of contrast agents is different from other drugs, and it needs to be used with corresponding equipment. In recent years, China is in the growth period of imaging equipment.phenyl (5-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-5-oxo-2,2-diphenylpentyl)carbamate Secretary of Health Francisco Duque said authorities are working with the Chinese embassy to respectfully handle the remains of the man while following international protocol to contain the disease.9-(2-Homoveratrylcarbamoyl-aethyl)-triptycen Secretary of Health Francisco Duque said authorities are working with the Chinese embassy to respectfully handle the remains of the man while following international protocol to contain the disease.3-(13,24,33,43,53,63-hexaoxin-2-yl)-1-(7-(5-hydroperoxy-13,24,33,43,54,63-hexaoxin-2-yl)-5-(hydroxy-24-trioxidaneyl)-13,24,33,43,54,63,74,83,94-pentaoxolo[3,2]hexaoxin-2-yl)-14-trioxidan-1-one Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.“Administrative Measures for the Joint Review, Review and Approval of Raw Materials, Medicinal Auxiliaries and Pharmaceutical Packaging Materials and Pharmaceutical Preparations” (Consultation Draft) issued by the State Food and Drug Administration in December 2017. Supervision departments no longer accept applications for registration of APIs, pharmaceutical excipients, and packaging materials.
Product Name | |
---|---|
3,4-Difluorobenzyl chloride | View Details |
2,2,3,3-tetramethylcyclopropanecarboxylic acid | View Details |
Fmoc-D-Cys(phacm) | View Details |